J-MK received consulting fees, paid advisory boards, lecture fees and/or grant support from Amgen, Eli Lilly, Glaxo Smith Kline, Merck Sharp & Dohme, Novartis, Roche, Sanofi Aventis, Servier and Warner Chilcott. J-YR received consulting fees or paid advisory boards from Amgen, Glaxo Smith Kline, Eli Lilly, Merckle, Negma, Novartis, NPS, Nycomed, Servier, Theramex, UCB and Wyeth, lecture fees from Merck Sharp and Dohme, Eli Lilly, Rottapharm, IBSA, Genevrier, Novartis, Servier, Roche, GlaxoSmithKline, Teijin, Teva, Ebewee Pharma, Zodiac, Analis, HDAC inhibitor Theramex, Nycomed, Novo-Nordisk, Nolver, and grant support from Merck Sharp and Dohme, Eli Lilly, Rottapharm, IBSA, Genevrier, Novartis,

Servier, Roche, GlaxoSmithKline, Teijin, Teva, Ebewee Pharma, Zodiac, Analis, Theramex, Nycomed, Novo-Nordisk, Nolver. SB reports institutional research support Erastin supplier and consulting fees from Amgen, Novartis and Servier. MLB was consultant and grant recipient from Amgen, Eli Lilly, MSD, Novartis, NPS, Roche and Servier. CP has received honoraria and consulting fees from Amgen, Eli Lilly, Medtronic, Merck, Novartis and Servier. WD is an employee from Amgen and shareholder from Eli Lilly and Amgen. J-PD has received consulting

or advisory board fees from Novartis, lecture fees from Amgen, and grant support from Servier, Novartis, and from Amgen. ADP was speaker and/or scientific advisor for Amgen, Lilly, Merck Sharp & Dohme, Novartis and Active Life Technologies, and received research funding from Amgen. JAK has received consulting fees/research funding from Amgen, Lilly, Servier and Warner-Chilcott. EMcC declares paid advisory boards from Amgen, Medtronic and Tethys, speakers honoraria from Amgen, Bayer, GE Lunar, Glaxo Smith Kline, Hologic, Eli Lilly, Medtronic,

Merck, Novartis, Pfizer, Servier, Warner-Chilcott, and research funding from Amgen, Innovus 3i, Eli Lilly, Novartis, and Pfizer. BM is an employee and shareholder from Eli Lilly. EO has received research funding from Eli Lilly, Amgen and Merck. He has been a consultant for Eli Lilly, Merck, Amgen and Wright Medical Technology. JDR gives advice to and lectures for Amgen, Glaxo Smith Kline, Leo Pharma, Merck and Servier. GW declares consulting fees or paid advisory boards from Novartis, lecture fees from Eli Lilly, Servier, Theramex, and clinical trial fees as investigator from Amgen, Eli Lilly, Merck Sharp & Dohme, Nycomed, Roche, and Servier. RR declares paid advisory boards or speaker bureau for Merck Sharp and Dohme, Eli Lilly, Amgen, Servier and Danone. We thank P. Belissa-Mathiot for her valuable input to this review. We thank Dr Vanessa Gray-Schopfer, OmniScience SA and Wolters Kluwer Pharma Solutions France who provided medical writing services on behalf of the ESCEO panel.